Minerva Neurosciences | NERV - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Adma Biologics USD 431.19M 32.87M 2025-09
ALKERMES USD 1.82B 85.86M 2025-12
Alterity Therapeutics Limited AUD 22.81M 5.29M 2023-06
AstraZeneca USD 48.67B 2.78B 2025-12
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Cipla INR 329.19B 16.3B 2025-09
Clal Biotechnology ILS 121.41M 4.62M 2023-12
Compugen USD 43.83M 6.43M 2025-09
CSL USD 18.66B 2.75B 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Esperion Therapeutics USD -451.36M 17.85M 2025-09
GlaxoSmithKline GBP 16.38B 229M 2025-12
Grifols EUR 6.08B 34.72M 2025-09
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
J&J USD 78.47B 0 2025-09
Merck USD 51.85B 2.79B 2025-09
Minerva Neurosciences USD -34.58M 2.47M 2025-09
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novartis USD 44.75B 2.7B 2025-09
Novavax USD -156.67M 194.3M 2025-09
Pfizer USD 92.8B 4.11B 2025-09
Roche Holding CHF 33.8B 758M 2025-12
Sanofi EUR 71.71B 1.55B 2025-12
Takeda JPY 7.64T 513.39B 2025-12
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12